SCHLAGWORTE: Nuclidium
‘Copper theranostics bring diagnosis and treatment together in a highly effective...
Dr Leila Jaafar-Thiel, CEO of Nuclidium, explains how the company’s copper-based radiotheranostic approach will become a milestone in precision oncology for an improved individual...
Nuclidium: CHF 26 million Series B extension round
Nuclidium, a clinical-stage radiopharmaceutical company, has announced the successful closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension round, bringing...